A fixed-dose combination (FDC) medication primarily indicated for the symptomatic relief of cough and cold. It combines a centrally-acting antitussive (Dextromethorphan), a nasal decongestant (Phenylpropanolamine), a second-generation antihistamine (Cetirizine), and a topical soothing agent (Menthol). This combination targets multiple symptoms of upper respiratory tract infections (URTI) and allergic rhinitis, providing relief from dry cough, nasal congestion, rhinorrhea, and sneezing. It is widely used in the Indian OTC market for acute, self-limiting conditions.
Adult: One tablet/capsule every 8 to 12 hours. Maximum: 2 doses in 24 hours. Should not exceed 3 days of use without medical advice.
Note: Administer orally with or without food. Taking with food may reduce gastric irritation. Swallow whole with a full glass of water. Do not crush or chew. Avoid taking late in the evening to prevent insomnia from PPA. Do not exceed the recommended dose or duration.
The combination works synergistically on different pathways of the cough reflex and cold symptoms. Dextromethorphan suppresses the cough center in the medulla oblongata. Phenylpropanolamine causes vasoconstriction in the nasal mucosa via alpha-1 adrenergic receptors, reducing edema and congestion. Cetirizine competitively inhibits histamine at H1-receptors, reducing allergic symptoms like sneezing and rhinorrhea. Menthol activates cold-sensitive TRPM8 receptors in the respiratory tract, providing a cooling sensation and mild local anesthetic effect that can soothe throat irritation.
Pregnancy: Category C (US FDA). Risk cannot be ruled out. PPA is a vasoconstrictor; theoretical risk of reduced uterine blood flow. Cetirizine is Category B but in combination, use is not recommended. Avoid, especially in first trimester. Use only if potential benefit justifies potential risk to the fetus.
Driving: NOT ADVISABLE. The combination can cause significant drowsiness, dizziness, and blurred vision. Patients should not drive or operate heavy machinery until they know how the medication affects them.
| Monoamine Oxidase Inhibitors (MAOIs) - Phenelzine, Selegiline | Risk of severe hypertensive crisis, hyperpyrexia. Potentially fatal. | Contraindicated |
| Other Sympathomimetics (Pseudoephedrine, Ephedrine, Salbutamol) | Additive pressor effects, increasing risk of hypertension, tachycardia, and arrhythmias. | Major |
| Alcohol, CNS Depressants (Benzodiazepines, Opioids, Barbiturates) | Additive CNS depression with Dextromethorphan and Cetirizine, impairing alertness and coordination. | Major |
| Serotonergic Drugs (SSRIs - Fluoxetine, Sertraline; SNRIs; TCAs; Tramadol) | Increased risk of serotonin syndrome with Dextromethorphan (NMDA/Sigma activity). | Major |
| Antihypertensives (Beta-blockers, ACE Inhibitors) | PPA may antagonize the blood pressure-lowering effect. | Moderate |
| CYP2D6 Inhibitors (Quinidine, Fluoxetine, Paroxetine) | Increase Dextromethorphan and PPA levels, increasing toxicity risk. | Moderate |
| Anticholinergics (Atropine, Tricyclic Antidepressants, Oxybutynin) | Additive anticholinergic effects with Cetirizine (dry mouth, urinary retention, constipation). | Moderate |
Same composition (Dextromethorphan Hydrobromide (10mg) + Menthol (1.5mg) + Cetirizine (2mg) + Phenylpropanolamine (12mg)), different brands: